title: Antibodies against Hsp60 and Hsp65 in the sera of women with ovarian cancer.
abstract: BACKGROUND
  The aim of this study was to evaluate the concentrations of IgG antibodies against Hsp60 and Hsp65 in sera of patients with ovarian cancer at various stages of clinical progress and for different histopathological types of disease.
  
  
  METHODS
  Serum samples from 149 patients with ovarian carcinoma and 80 healthy women were investigated. The concentrations of anti-Hsp60 and anti-Hsp65 antibodies were determined using the enzyme-linked immunosorbent assay technique.
  
  
  RESULTS
  The mean concentrations of anti-Hsp60 and anti-Hsp65 antibodies in the patients with ovarian cancer did not differ significantly from the mean levels in healthy women. Analysis in relation to the clinical progression stage showed that the concentrations of these antibodies were higher when the neoplastic process was less advanced and at early stages significantly higher than in control group. Mean concentrations of both antibodies were not significantly different in relation to the histological type of the ovarian cancer. The use of chemotherapy as a primary anticancer treatment did not cause a significant change in the concentration of anti-Hsp60 antibodies, but the mean level of anti-Hsp65 after this treatment was significantly higher than in control group.
  
  
  CONCLUSIONS
  The immunological response to Hsp60/65 is increased in early clinical stages of ovarian cancer and the level of anti-hsp60/65 antibodies may be then a helpful diagnostic marker. Even antibodies against highly homologous Hsps may be cross-reactive only partially and differ by some functional properties.
authors.affiliation: Department of Gynaecology, Obstetrics and Oncological Gynaecology, Medical University of Silesia, Batorego 15, 41-902 Bytom, Poland. piotr@bodzek.pl.
authors.forename: Piotr
authors.initials: P
authors.lastname: Bodzek
authors.forename: Robert
authors.initials: R
authors.lastname: Partyka
authors.forename: Aleksandra
authors.initials: A
authors.lastname: Damasiewicz-Bodzek
mesh_terms: D000368:Aged; D000918:Antibody Specificity; D001323:Autoantibodies / Q000097:blood*; D014408:Biomarkers, Tumor / Q000097:blood*; D002277:Carcinoma / Q000097:blood* / Q000276:immunology* / Q000473:pathology; D016022:Case-Control Studies; D018834:Chaperonin 60 / Q000276:immunology*; D003429:Cross Reactions; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006360:Heat-Shock Proteins / Q000276:immunology*; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood*; D008875:Middle Aged; D024101:Mitochondrial Proteins / Q000276:immunology*; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000097:blood* / Q000276:immunology* / Q000473:pathology; D011237:Predictive Value of Tests
chemical_list: D001323:Autoantibodies; D014408:Biomarkers, Tumor; D018834:Chaperonin 60; D006360:Heat-Shock Proteins; D007074:Immunoglobulin G; D024101:Mitochondrial Proteins; C060293:HSPD1 protein, human